Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase I Study to re-Investigate the Safety, Tolerability and Pharmacodynamic Effects of SLIT(Tablets) With Recombinant Bet v1 Given in Single Rising Doses and in Multi Dose Regimens to Subjects Sensitised to Birch Pollen

NCT00889460 is registered in ClinicalTrials.gov with Stallergenes Greer as lead sponsor.

NCT NCT00889460
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00889460 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase I Study to re-Investigate the Safety, Tolerability and Pharmacodynamic Effects of SLIT(Tablets) With Recombinant Bet v1 Given in Single Rising Doses and in Multi Dose Regimens to Subjects Sensitised to Birch Pollen
Lead sponsor
Stallergenes Greer
Phase
Phase 1
Overall status
Completed
Start date
November 30, 2007
Completion date
April 30, 2008
Enrollment
55 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

birch pollen-related rhinoconjunctivitis, rhinitis, allergic, seasonal